Multimeric Stability of Human C-reactive Protein in Archived Specimens

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Li, Qiling ^a,b   Kang, Ting ^b   Tian, Xiaohua ^b   Ma, Yamin ^b   Li, Min ^c   Richards, Jendai ^b   Bythwood, Tameka ^b   Wang, Yueling ^a   Li, Xu ^a   Liu, Dong ^b   Ma, Li ^b   Song, Qing ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; NONHUMAN; PRESERVATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; RAT; STORAGE TEMPERATURE; TISSUE LEVEL; TRANSGENIC RAT; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CRYOPRESERVATION; HUMANS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; RATS; RATS, TRANSGENIC; TEMPERATURE; TIME FACTORS; TISSUE PRESERVATION;

EID: 84875024932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058094     Document Type: Article

References (46)

1. Tillett WS, Francis T, (1930) Serological Reactions in Pneumonia with a Non-Protein Somatic Fraction of Pneumococcus. J Exp Med 52: 561-571.
2. Abernethy TJ, Avery OT, (1941) The Occurrence during Acute Infections of a Protein Not Normally Present in the Blood: I. Distribution of the Reactive Protein in Patients' Sera and the Effect of Calcium on the Flocculation Reaction with C Polysaccharide of Pneumococcus. J Exp Med 73: 173-182.
3. Kones R, (2010) Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther 4: 383-413.
4. Yeh ET, Willerson JT, (2003) Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370-371.
5. Ridker PM, Buring JE, Cook NR, Rifai N, (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397.
6. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, et al. (2009) ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 54: 1336-1363.
7. Pepys MB, Hirschfield GM, (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334.
10. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, et al. (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56: 872-878.
11. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ, (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590.
12. Pfutzner A, Forst T, (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8: 28-36.
13. Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, et al. (2012) Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 41: 866-871.
14. Visvanathan S, Rahman MU, Hoffman GS, Xu S, Garcia-Martinez A, et al. (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology (Oxford) 50: 2061-2070.
15. Lee GY, Jang SY, Ko SM, Kim EK, Lee SH, et al. (2012) Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: Analysis of 204 Korean patients at a single center. Int J Cardiol 159: 14-20.
16. Goel R, Danda D, Mathew J, Edwin N, (2010) Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 29: 329-332.
17. Pirro M, Bocci EB, Di Filippo F, Schillaci G, Mannarino MR, et al. (2012) Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment. J Intern Med 272: 177-184.
18. Nothnagl T, Leeb BF, (2006) Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica. Drugs Aging 23: 391-402.
19. Harada K, (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33: 805-810.
20. Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M, (1997) Serum C-reactive protein levels in patients with Kawasaki disease: from the results of nation-wide surveys of Kawasaki disease in Japan. Acta Paediatr 86: 613-619.
21. Bhutto IA, Baba T, Merges C, Juriasinghani V, McLeod DS, et al. (2011) C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration. Br J Ophthalmol 95: 1323-1330.
22. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH, (2010) C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 117: 1982-1988.
23. Lei KJ, Liu T, Zon G, Soravia E, Liu TY, et al. (1985) Genomic DNA sequence for human C-reactive protein. J Biol Chem 260: 13377-13383.
24. Woo P, Korenberg JR, Whitehead AS, (1985) Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem 260: 13384-13388.
25. Diehl EE, Haines GK 3rd, Radosevich JA, Potempa LA, (2000) Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319: 79-83.
26. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, et al. (2008) C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 28: 2239-2246.
27. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, et al. (2009) Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105: 128-137.
28. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S, (2005) Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288: H2031-2041.
29. Lopez-Garcia E, Schulze MB, Meigs JB, Manson JE, Rifai N, et al. (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 135: 562-566.
30. Kilpatrick JM, Volanakis JE, (1991) Molecular genetics, structure, and function of C-reactive protein. Immunol Res 10: 43-53.
31. Robey FA, Jones KD, Tanaka T, Liu TY, (1984) Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem 259: 7311-7316.
32. Thompson D, Pepys MB, Wood SP, (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7: 169-177.
33. Khreiss T, Jozsef L, Potempa LA, Filep JG, (2004) Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 110: 2713-2720.
34. Khreiss T, Jozsef L, Potempa LA, Filep JG, (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109: 2016-2022.
35. Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H, (1988) Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 12: 391-405.
36. Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, et al. (2005) Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112: 1016-1023.
37. Park YS, Kim JS, (2012) Obesity phenotype and coronary heart disease risk as estimated by the framingham risk score. J Korean Med Sci 27: 243-249.
38. Sims M, Diez-Roux AV, Dudley A, Gebreab S, Wyatt SB, et al. (2012) Perceived Discrimination and Hypertension Among African Americans in the Jackson Heart Study. Am J Public Health.
39. Khreiss T, Jozsef L, Potempa LA, Filep JG, (2005) Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97: 690-697.
40. Zouki C, Haas B, Chan JS, Potempa LA, Filep JG, (2001) Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 167: 5355-5361.
41. Khreiss T, Jozsef L, Hossain S, Chan JS, Potempa LA, et al. (2002) Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 277: 40775-40781.
42. Zhao J, Shi XH, (2010) Study of the interaction of the C-reactive protein monomer with the U937 monocyte. Cell Mol Biol Lett 15: 485-495.
43. Ross CA, Poirier MA, (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl) (): S10-17.
44. Dobson CM, (2004) Protein chemistry. In the footsteps of alchemists. Science 304: 1259-1262.
45. Kelly JW, (2006) Structural biology: proteins downhill all the way. Nature 442: 255-256.
46. Okemefuna AI, Stach L, Rana S, Buetas AJ, Gor J, et al. (2010) C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer. J Biol Chem 285: 1041-1052.